IGF-1 LR3 cycle length

The standard IGF-1 LR3 cycle is 4–6 weeks. This is shorter than nearly any other peptide cycle on the site (BPC-157 runs 4–8 weeks for injury-specific work, GH secretagogues run 12–16 weeks for body-comp goals), and the constraints are real: receptor desensitization caps the marginal benefit of longer cycles, and the cancer-axis caveat means longer cumulative IGF-1 exposure carries weight that doesn't apply to gentler peptides. The cycle-length conversation also has a year-level dimension — total weeks per year matters more than any single cycle length.

Why 4–6 weeks is the standard

Three reasons compound to set the cycle ceiling:

1. Receptor desensitization. Sustained supraphysiologic IGF-1 receptor activation downregulates receptor expression at the cell surface. By weeks 5–6, the marginal anabolic signal per mcg of injected peptide drops noticeably. Adding more weeks doesn't recover the early-cycle response.
2. Cancer-axis exposure. IGF-1 elevation is implicated in cellular proliferation pathways. The relevant exposure variable is cumulative supraphysiologic IGF-1 receptor activation, and longer cycles directly increase that variable. This is the dominant constraint for any user with even partial caution about long-term safety.
3. Side-effect accumulation. Carpal tunnel symptoms, joint aches, and persistent fatigue tend to creep in past week 5–6. Acute hypoglycemia sensitivity also drifts as the cycle extends.

Combined: the 4–6 week window is where benefit is highest and risk creep is lowest.

What the typical cycle looks like

A defensible 5-week cycle structure:

This is one pattern among many. Some users run flat 30 mcg/day for 5 weeks. Some ramp to 50 mcg/day for weeks 3–5. The structural point is: ramp in, hold, ramp out is unnecessary for IGF-1 LR3 (no withdrawal effect like a steroid taper) — you can stop at full dose without issue.

What longer cycles look like, and why most experienced users avoid them

You'll see reports of 8-week, 10-week, and even 12-week IGF-1 LR3 cycles. The pattern:

• Weeks 1–4: clear anabolic signal, expected side-effect tolerability
• Weeks 5–6: side effects accumulating, signal flattening
• Weeks 7–8: side effects dominant, signal modest
• Weeks 9+: receptor downregulation, diminishing returns, cancer-axis exposure rising

The math doesn't work for most users. The benefit is concentrated in the first 4–6 weeks; the risk accrues linearly with time. Doubling cycle length doesn't double the benefit — it adds cost, side effects, and exposure with diminishing return.

Why short cycles (under 3 weeks) don't work either

Conversely, very short cycles (1–2 weeks) usually don't deliver clean signal:

• IGF-1 LR3 takes 5–7 days to reach steady-state plasma levels
• Adaptive tissue response (hypertrophy, body comp) takes another 1–2 weeks to express
• Subjective signal (training quality, recovery) often doesn't appear until week 2–3

A 2-week cycle has you stopping right as the peptide is hitting full effect. If you're doing a focused anabolic block, 4 weeks is the realistic minimum.

Off-period rules

After the cycle, take a real break. Standard reported off-periods:

The rationale:

• Allows IGF-1 receptor expression to recover from desensitization
• Allows endogenous GH/IGF-1 axis to resume normal function (IGF-1 LR3 suppresses both via feedback)
• Reduces cumulative cancer-axis exposure
• Surfaces any post-cycle issues (rebound insulin resistance, persistent symptoms) before the next cycle obscures them

Some users use the off-period to run a GH secretagogue cycle instead. This is reasonable as long as total combined GH/IGF-1-axis activity isn't constant year-round.

Year-over-year cumulative cycles

This is the most-overlooked dimension. A single 5-week cycle is a defensible exposure window. Three 5-week cycles per year (15 weeks total) is meaningfully more cumulative exposure. Six cycles per year is in territory where the cancer-axis caution becomes non-trivial.

A reasonable framework:

Most experienced users settle into 2–3 cycles per year max, often timed around training blocks (offseason, pre-competition, etc.).

The "always-on" anti-pattern

Some users run continuous low-dose IGF-1 LR3 (10–15 mcg/day, no cycling) on the theory that "lower dose, longer time" reduces risk. This is the wrong direction:

• Continuous exposure is the variable the cancer epidemiology cares most about
• Low-dose continuous still produces sustained receptor activation
• You lose the opportunity for off-cycle recovery
• Subjective benefit at very low doses is minimal anyway

If a goal can be addressed by low-dose continuous, a GH secretagogue is the better tool. IGF-1 LR3 is a focused short-cycle peptide, not a continuous-low-dose peptide.

Cycle length when stacking with GH secretagogues

When IGF-1 LR3 is stacked with Ipamorelin + CJC-1295 (no DAC), the stack inherits the IGF-1 LR3 ceiling. You don't run the secretagogue for 12 weeks because you stacked it with IGF-1 LR3. The cycle is gated by the IGF-1 LR3 component:

• Synchronous cycle: both components run weeks 1–5; both stop at week 5
• Layered cycle: secretagogue runs 12 weeks, IGF-1 LR3 layered in for weeks 5–10 of that cycle

Most users run synchronous. See stacking IGF-1 LR3 with GH peptides.

Indicators to shorten or stop a cycle early

What baseline and end-of-cycle labs to run

Running these pre-cycle and end-of-cycle for a few cycles establishes your individual response pattern.

The honest take

IGF-1 LR3 is a focused short-cycle tool. The 4–6 week window captures essentially all of the available benefit. Longer cycles add cost, side effects, and cumulative cancer-axis exposure without recovering early-cycle anabolic signal. The most experienced users in this category aren't running longer cycles — they're running 2–3 well-planned 5-week cycles per year with proper off-periods and lab monitoring. That's the durable pattern.

Related reading

• IGF-1 LR3 dosing protocol
• IGF-1 LR3 cancer concerns
• IGF-1 LR3 side effects
• Stacking IGF-1 LR3 with GH peptides